Pierre Charneau

28 Rue Du Dr. Roux
Paris, 75015, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Eradication of pre-clinical prostate tumors by a lentiviral vector-based immunotherapy.

Eradication of pre-clinical prostate tumors by a lentiviral vector-based immunotherapy.

Journal: Molecular therapy. Oncology

Published: March 09, 2026

Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike protein.

Optimized pipeline for generating highly potent neutralizing Affitins: Application to SARS-CoV-2 spike protein.

Journal: International journal of biological macromolecules

Published: May 02, 2025

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses.

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses.

Journal: Vaccine

Published: April 23, 2025

Shared neoantigens for cancer immunotherapy.

Shared neoantigens for cancer immunotherapy.

Journal: Molecular therapy. Oncology

Published: April 21, 2025

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy.

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy.

Journal: Scientific reports

Published: March 17, 2025

Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.

Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.

Journal: NPJ vaccines

Published: February 21, 2025

Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.

Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.

Journal: Expert review of vaccines

Published: July 09, 2024

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.

Journal: Journal of virology

Published: April 02, 2024

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

Journal: NPJ vaccines

Published: November 30, 2023

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.

Journal: Frontiers in immunology

Published: April 18, 2023

Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.

Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.

Journal: EMBO molecular medicine

Published: March 20, 2023

Lentiviral Vectors as a Vaccine Platform against Infectious Diseases.

Lentiviral Vectors as a Vaccine Platform against Infectious Diseases.

Journal: Pharmaceutics

Published: February 08, 2023

Showing 1-12 of 53

Last Updated: 09/26/2026